Meeting Minutes: Drug Formulary Committee

Date & Time: August 23, 2017, 5-9PM
Minutes prepared by: Nina Bandali and Dave Hoang
Location: Elmer Andersen Building, Room 2340, 540 Cedar Street, St. Paul, MN 55101

Attendance

- Members in attendance: Margaret Artz, RPh., Ph.D., Kyle Lehenbauer, M.D., Stacey Ness, Pharm.D., James Phillips, M.D., Kelly Ruby, Pharm.D., Michael Sprehe, M.D., Stuart Williams, J.D., RPh
- Members absent: Monica Brands, RPh., Al Heaton, RPh., Kathryn Lombardo, M.D., Eric Meininger, M.D.
- DHS staff present: Jeff Schiff, M.D., MBA, Chad Hope, Pharm.D., Dave Hoang, Pharm.D., MBA, Mary Beth Reinke, Pharm.D., MSA.
- Others in attendance: Nina Bandali, Pharm.D., Ariane Casey, Pharm.D.
- The committee congratulated Dr. Stacey Ness for her reappointment.

Report of the Chair

No updates

Approval of Minutes

Minutes from the May 2017 meeting were reviewed and approved.

Biosimilars: An Overview

- DHS Clinical Pharmacist provided an overview on biosimilars.
- The committee recommended by a unanimous vote to adopt a blanket PA policy for biosimilars and manage these agents based on cost.

New Specialty Drugs for Continued PA

- The committee discussed Emflaza and recommended to the department by a unanimous vote that Emflaza remain on PA with a slight modification to the criteria to remove “home” from the list of locations where behavioral changes negatively impact function.
- The committee discussed Kisqali and recommended to the department by a unanimous vote that Kisqali remain on PA. The committee also recommended that language be added to define postmenopause.
The committee discussed Siliq and recommended to the department by a unanimous vote that Siliq remain on PA. The committee also recommended the additional language defining stabilization for this class and the addition of Crohn’s disease as denial criteria for Siliq.

The committee discussed Bavencio and recommended to the department by a unanimous vote that Bavencio remain on PA. The committee also recommended changing the renewal approval to 6 months.

The committee discussed Dupixent and recommended to the department by a unanimous vote that Dupixent remain on PA.

The committee discussed Ocrevus and recommended to the department by a unanimous vote that Ocrevus remain on PA. The committee also recommended that demonstrating improvement or lack of progression should only be applied to RRMS patients. For PPMS, a lack of meaningful progression should be applied.

The committee discussed Austedo and recommended to the department by a unanimous vote that Austedo remain on PA. The committee also recommended that chart notes be required to demonstrate appropriate screening for history of untreated or inadequately treated depression.

The committee discussed Xermelo and recommended to the department by a unanimous vote that Xermelo remain on PA.

New Drugs for Continued PA

The committee discussed Airduo Respiclick and the authorized generic and recommended to the department by a unanimous vote that both remain on PA. The committee also recommended that the department manage this category based on cost/availability.

The committee discussed Bevespi Aerosphere and Utibron Neohaler and recommended to the department by a unanimous vote that both remain on PA. The committee also recommended that the department manage this category based on cost/availability.

Adjournment

The meeting was adjourned at 7:50PM Central Time